Apac Point Care Testing Poct Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2022 –2029 |
 Marktgröße (Basisjahr) | USD 29.00 Billion |
 Marktgröße (Prognosejahr) | USD 64.46 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
|
Asia-Pacific Point-of-Care Testing (POCT) Market, By Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies) – Industry Trends and Forecast to 2029
Market Analysis and Size
Point-of-care testing, which is defined as testing that may be done in close proximity to the patient and allows a medical choice to be taken right away based on the results and monitoring. point-of-care testing (POCT), also known as with-patient testing, allows doctors to assess accurate real-time, lab-quality diagnostic results in minutes rather than hours. It guarantees that patients get the most effective and efficient care possible, whenever and wherever they need it.
Data Bridge Market Research analyses that the point-of-care testing (POCT) market which was USD 29 billion in 2021, would rocket up to USD 64.46 billion by 2029, and is expected to undergo a CAGR of 10.5% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
POC tests are not as highly preferred as central laboratory tests because of low volume and high cost. This puts additional strain on the billing system, which must give distinct codes for POC tests. This might result in billing errors by inexperienced or newly hired employees, as well as failure to enter data into the data management system due to mismatched test codes.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies) |
|
Countries Covered |
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC) |
|
Market Players Covered |
Abbott (U.S), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S), Danaher (U.S), Sekisui Diagnostics (U.S), Trinity Biotech (Ireland), bioMérieux (France), EKF Diagnostics (Germany), AccuBioTech Co., Ltd. (China), Instrumentation Laboratory (U.S), Beckman Coulter, Inc. (U.S), PTS Diagnostics (U.S), Nova Biomedical (U.S), Chembio Diagnostics, Inc. (U.S), Quidel Corporation (U.S) and Sienco, Inc (U.S) |
|
Market Opportunities |
|
Point-of-Care Testing (POCT) Market Dynamics
Drivers
- Upward trend in disease prevalence in the developing countries
Chronic diseases and acute infections are on the rise in developing countries, owing to a lack of health awareness, poor medical infrastructure, and a sedentary lifestyle, among other causes. As a result of these circumstances, diagnosis and treatment are delayed, as is the quality of care obtained. The need for point-of-care tests for rapid diagnosis is growing due to their convenience of use, cost-effectiveness, and small product size.
- Benefits related with OTC-based test
The point of care testing market for TC tests is expected to develop at a 7.1% CAGR through 2027, owing to an increase in OTC testing such as pregnancy tests and blood glucose tests that deliver results in a matter of seconds. These examinations do not necessitate the use of a skilled specialist and may be performed by individuals themselves, propelling the industry forward. The First Response kit, for example, is a quick pregnancy test that provides a response in 60 seconds. Accu-Chek active blood glucose metre kits also give customers with readings in 5 seconds, boosting market demand.
- Increasing incidence rate of diabetes and obesity lead to cardiovascular illness
The increased prevalence of diabetes and obesity, the point of care testing market for cardio metabolic testing is predicted to exceed USD 5.3 billion by 2027. The cardiometabolic test also determines the percentage level of Docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA) in red blood cell membrane.This also aids in the identification of new risk factors for cardiac arrest and other heart-related disorders.
Opportunities
- Technological advancement in lateral flow assay
The market for lateral flow assays in point of care testing is expected to reach USD 11.8 billion by 2027. The industry's growth will be aided by the launch of novel products that will allow for rapid advancement in the research and development (R&D) of point-of-care testing (POCT) diagnostic tools. In addition, advances in component materials, reader technologies, reagents, and sensitivity increase have made quantitative results more possible with the use of lateral flow assay, supporting sector growth.
Restraints/Challenges
- Stringent regulatory policies
Due to tight and time-consuming regulatory requirements, the point of care testing industry is growing slowly. With the expanding area of use and increased adoption in developing economies, regulators are placing a greater emphasis on point-of-care testing (POCT) compliance, safety, and usability. Point-of-care testing are classed as class II medical devices by the US Food and Drug Administration. These devices provide a reasonable guarantee of the device's effectiveness and safety.
- Lack of alignment with definitive central lab methods
Unsuitable indications for the performance of the test, inappropriate sampling times and techniques, a lack of information about the patient's condition, and other factors such as fasting before functional tests or variations in posture/position during similar tests are all examples of pre-analytical errors for POC testing.
This point-of-care testing (POCT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point-of-care testing (POCT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Point-of-Care Testing (POCT) Market
The growing use of point-of-care tests that can quickly identify COVID-19, the point-of-care diagnostics market will rise significantly in 2022. Point-of-care testing has become an important diagnostic technique due to the necessity for quick diagnostic results. Rapid antigen testing kits that can be utilised efficiently in point-of-care settings are in high demand due to the rapidly increasing number of COVID-19 cases and the growing pressure on governments to enhance patient management. Different significant reasons projected to fuel the long-term growth of the point-of-care diagnostics market are the rising prevalence of other respiratory disorders around the world, the shift toward decentralised diagnostics, and enhanced access to point-of-care devices through online platforms.
Recent Development
Roche introduced its Cobas Pulse System in select countries accepting the CE Mark in January 2022. This is the latest generation of linked point-of-care solutions for professional blood glucose management from Roche Diagnostics.
In October 2021, Thermo Fisher Scientific announced that it had received FDA Emergency Use Authorization (EUA) to run COVID-19 tests with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device, a high-throughput, automated COVID-19 testing system on the Amplitude Solution, using a new saliva sample collection method.
The SPECIFIC REVEAL Rapid AST system was co-exclusively distributed in Europe by bioMérieux and Specific Diagnostics in June 2021. The system works in tandem with bioMérieux's BIOFIRE BCID2.
Asia-Pacific Point-of-Care Testing (POCT) Market Scope
The point-of-care testing (POCT) market is segmented on the basis of product, technology, prescription, application, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Glucose Monitoring
- Strips
- Meters
- Lancets
- Cardiometabolic testing
- Cardiac marker testing
- hsTnl
- BNP
- D-dimer
- CK-MB
- Myoglobin
- Others
- Blood gas/electrolytes testing
- HBA1C testing
- Infectious disease testing
- Influenza testing
- HIV testing
- Hepatitis C testing
- Sexually Transmitted Disease (STD) testing
- Healthcare-Associated Infection (HAI) testing
- Respiratory infection testing
- Tropical disease testing
- Other infectious diseases testing
- Coagulation testing
- PT/INR testing
- Activated Clotting Time (ACT/APTT) testing
- Pregnancy and fertility testing
- Pregnancy testing
- Fertility testing
- Tumor/Cancer marker testing
- Urinalysis testing
- Cholesterol testing
- Hematology testing
- Drugs-of-abuse testing
- Fecal occult testing
- Others
Technology
- Lateral flow assays
- Dipsticks
- Microfluidics
- Molecular diagnostics
- Immunoassays
- Agglutination assays
- Flow-through
- Solid phase
- Biosensors
Prescription
- OTC testing
- Prescription-based testing
Application
- Cardio metabolic testing
- Infectious disease testing
- Nephrology testing
- Drug-of-Abuse (DoA) testing
- Blood glucose testing
- Pregnancy testing
- Cancer biomarker testing
- Other applications
End-user
- Hospitals
- Diagnostic centers
- Research laboratories
- Home-care settings
- Others
Distribution Channel
- Direct tender
- Retail Pharmacies
Point-of-Care Testing (POCT) Market Regional Analysis/Insights
The point-of-care testing (POCT) market is analysed and market size insights and trends are provided by country, product, technology, prescription, application end-user and distribution channel as referenced above.
The countries covered in the point-of-care testing (POCT) market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
China is expected to dominate the market because point-of-care testing (POCT) products in China have a massive application space in the fields of hospital operation, emergency department, intensive care, chronic disease prevention and control, public health emergencies, county-level medical institution construction, and new rural supportive medical care.
Japan will dominate the market due to an increasing number of people suffering from HIV and other illnesses, which will result in a high approval rate for point-of-care testing devices in the country. India is the dominant country due to the high prevalence of diseases among its people.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The point-of-care testing (POCT) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for point-of-care testing (POCT) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the point-of-care testing (POCT) market. The data is available for historic period 2010-2020.
Competitive Landscape and Point-of-Care Testing (POCT) Market Share Analysis
The point-of-care testing (POCT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to point-of-care testing (POCT) market.
Some of the major players operating in the point-of-care testing (POCT) market are:
- Abbott (U.S)
- F. Hoffmann-La Roche Ltd (Switzerland)
- BD (U.S)
- Siemens Healthcare Private Limited (Germany)
- Bio-Rad Laboratories, Inc. (U.S)
- Danaher (U.S)
- Sekisui Diagnostics (U.S)
- Trinity Biotech (Ireland)
- bioMérieux (France)
- EKF Diagnostics (Germany)
- AccuBioTech Co., Ltd. (China)
- Instrumentation Laboratory (U.S)
- Beckman Coulter, Inc. (U.S)
- PTS Diagnostics (U.S)
- Nova Biomedical (U.S)
- Chembio Diagnostics, Inc. (U.S)
- Quidel Corporation (U.S)
- Sienco, Inc (U.S)
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 LIST OF DISTRIBUTORS IN ASIA PACIFIC REGION FOR POINT-OF-CARE-TESTING MARKET
5 COVID-19 IMPACT ON ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
5.1 IMPACT ON DEMAND
5.2 PRICE IMPACT
5.3 IMPACT ON SUPPLY CHAIN
5.4 STRATEGIC DECISIONS FOR MANUFACTURERS
5.5 CONCLUSION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 GROWING POPULARITY OF WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES
6.1.4 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISING AWARENESS AND GOVERNMENT FUNDING
6.3.3 TECHNOLOGICAL ADVANCEMENTS IN POINT-OF-CARE TESTING DEVICES
6.4 CHALLENGE
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
7 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.1.1 GLUCOSE MONITORING PRODUCTS
7.1.1.1 STRIPS
7.1.1.2 METERS
7.1.1.3 LANCETS & LANCING DEVICES
7.1.2 INFECTIOUS DISEASE TESTING PRODUCTS
7.1.2.1 INFLUENZA
7.1.2.2 HIV TESTING PRODUCTS
7.1.2.3 HEPATITIS C
7.1.2.4 SEXUALLY TRANSMITTED DISEASE (STD)
7.1.2.5 HEALTHCARE-ASSOCIATED INFECTION (HAI)
7.1.2.6 RESPIRATORY INFECTION
7.1.2.7 TROPICAL DISEASE
7.1.2.8 OTHER INFECTIOUS DISEASE
7.1.3 CARDIOMETABOLIC TESTING PRODUCTS
7.1.3.1 BLOOD GAS/ELECTROLYTES
7.1.3.2 HBA1C TESTING PRODUCTS
7.1.3.3 CARDIAC MARKER TESTING PRODUCTS
7.1.3.4 LIPID TESTING KITS
7.1.4 PREGNANCY AND FERTILITY TESTING PRODUCTS
7.1.4.1 PREGNANCY TESTING PRODUCTS
7.1.4.2 FERTILITY TESTING PRODUCTS
7.1.5 HEMATOLOGY TESTING PRODUCTS
7.1.5.1 BLOOD ANAYZER
7.1.5.2 REAGENTS AND KITS
7.1.6 RAPID COAGULATION TESTING
7.1.6.1 COAGULATION ANALYZER
7.1.6.2 TESTING KIT
7.2 DRUGS-OF-ABUSE TESTING PRODUCTS
7.3 URINALYSIS TESTING PRODUCTS
7.4 CHOLESTEROL TESTING PRODUCTS
7.5 TUMOR/CANCER MARKER TESTING PRODUCTS
7.6 FECAL OCCULT TESTING PRODUCTS
7.7 OTHER POC PRODUCTS
8 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 BLOOD GLUCOSE
8.3 CARDIAC MONITORING LUCOSE
8.4 HAEMATOLOGY
8.4.1 WBC COUNT
8.4.2 DNA SEQUENCING REAGENTS & KITS
8.5 COAGULATION
8.6 WHOLE BLOOD ANALYSIS
8.6.1 BLOOD GASES
8.6.2 ELECTROLYTES & METABOLITES
8.7 VITAL SIGN MONITORING
8.7.1 HEART RATE
8.7.2 BLOOD PRESSURE
8.7.3 RESPIRATORY RATE 59.37
8.7.4 TEMPERATURE
8.8 NON- INVASIVE SPO2 MONITORING
8.9 NON- INVASIVE PCO2 MONITORING
8.1 BLOOD TRANSFUSION
9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM
9.1 OVERVIEW
9.2 LATERAL FLOW ASSAYS /IMMUNOCHROMATOGRAPHY TESTS
9.3 DIPSTICKS
9.4 MOLECULAR DIAGNOSTICS ENOME SEQUENCING
9.5 IMMUNOASSAYS
9.6 MICROFLUIDICS
10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE
10.1 OVERVIEW
10.2 OTC TESTING
10.3 PRESCRIPTION-BASED TESTING
11 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE
11.1 OVERVIEW
11.2 IMMUNOASSAYS
11.3 NUCLEIC ACID AMPLIFICATION TESTING
11.4 HAEMATOLOGY
11.5 CLINICAL CHEMISTRY ASSAYS
11.6 CELL-BASED ASSAYS
12 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER
12.1 OVERVIEW
12.2 CLINICS
12.3 HOME CARE
12.4 HOSPITALS
12.5 LABORATORIES
12.6 AMBULATORY SURGICAN CENTERS
12.7 OTHERS
13 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL PHARMACIES
14 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET BY COUNTRY
14.1 OVERVIEW
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 THAILAND
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC POINT-OF-CARE (POCT) MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F.HOFFMANN-LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHCARE PRIVATE LIMITED
17.2.1 COMPANY SNAPSHOT
17.2.1 PRODUCT PORTFOLIO
17.2.2 RECENT DEVELOPMENTS
17.3 BD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.4 DANAHER
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENTS
17.5 BIOMÉRIEUX SA
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ACCUBIOTECH CO.,LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 BECKMAN COULTER,INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 BIO-RAD LABORATORIES, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CHEMBIO DIAGNOSTICS SYSTEMS,INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 EKF DIAGNOSTICS
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 INSTRUMENTATION LABORATORY
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 NOVA BIOMEDICAL
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 PTS DIAGNOSTICS
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 QUIDEL CORPORATION
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 SEKISUI DIAGNOSTICS
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 SIENCO,INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 TRINITY BIOTECH
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 DIFFERENT ASSOCIATIONS FOR DIAGNOSTICS
TABLE 2 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 3 ASIA-PACIFIC GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 4 ASIA-PACIFIC INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 5 ASIA-PACIFIC CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 6 ASIA-PACIFIC PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 7 ASIA-PACIFIC HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 8 ASIA-PACIFIC RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 11 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 12 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT & SERVICE, 2018-2027 (USD MILLION)
TABLE 13 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY TECHNOLOGIES, 2018-2027 (USD MILLION)
TABLE 14 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 15 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 16 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 17 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 18 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 19 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 21 ASIA-PACIFIC CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 22 ASIA-PACIFIC INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 23 ASIA-PACIFIC PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 24 ASIA-PACIFIC CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 27 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 31 ASIA-PACIFIC POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 32 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 33 ASIA-PACIFIC POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 34 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 36 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 37 CHINA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 38 CHINA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 39 CHINA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 40 CHINA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 41 CHINA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 42 CHINA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 43 CHINA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 44 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 45 CHINA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 46 CHINA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 47 CHINA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 48 CHINA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 49 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 50 CHINA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 51 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 52 CHINA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 53 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 54 JAPAN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 55 JAPAN CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 56 JAPAN INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 57 JAPAN PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 58 JAPAN CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 59 JAPAN HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 60 JAPAN RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 61 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 62 JAPAN HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 JAPAN WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 64 JAPAN VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 65 JAPAN POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 66 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 67 JAPAN POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 68 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 69 JAPAN POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 70 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 71 INDIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 72 INDIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 73 INDIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 74 INDIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 75 INDIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 76 INDIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 77 INDIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 78 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 79 INDIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 INDIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 81 INDIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 82 INDIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 83 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 84 INDIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 85 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 86 INDIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 87 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 88 SOUTH KOREA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 89 SOUTH KOREA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 90 SOUTH KOREA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 91 SOUTH KOREA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 92 SOUTH KOREA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 93 SOUTH KOREA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 94 SOUTH KOREA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 95 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 96 SOUTH KOREA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 SOUTH KOREA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 98 SOUTH KOREA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 99 SOUTH KOREA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 100 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 101 SOUTH KOREA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 102 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 103 SOUTH KOREA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 104 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 105 GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 106 AUSTRALIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 107 AUSTRALIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 108 AUSTRALIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 109 AUSTRALIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 110 AUSTRALIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 111 AUSTRALIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 112 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 113 AUSTRALIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 114 AUSTRALIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 115 AUSTRALIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 116 AUSTRALIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 117 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 118 AUSTRALIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 119 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 120 AUSTRALIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 121 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 122 SINGAPORE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 123 SINGAPORE CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 124 SINGAPORE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 125 SINGAPORE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 126 SINGAPORE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 127 SINGAPORE HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 128 SINGAPORE RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 129 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 130 SINGAPORE HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 131 SINGAPORE WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 132 SINGAPORE VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 133 SINGAPORE POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 134 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 135 SINGAPORE POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 136 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 137 SINGAPORE POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 138 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 139 MALAYSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 140 MALAYSIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 141 MALAYSIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 142 MALAYSIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 143 MALAYSIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 144 MALAYSIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 145 MALAYSIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 146 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 147 MALAYSIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148 MALAYSIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 149 MALAYSIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 150 MALAYSIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 151 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 152 MALAYSIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 153 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 154 MALAYSIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 155 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 156 THAILAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 157 THAILAND CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 158 THAILAND INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 159 THAILAND PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 160 THAILAND CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 161 THAILAND HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 162 THAILAND RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 163 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 164 THAILAND HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 165 THAILAND WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 166 THAILAND VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 167 THAILAND POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 168 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 169 THAILAND POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 170 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 171 THAILAND POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 172 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 173 INDONESIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 174 INDONESIA CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 175 INDONESIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 176 INDONESIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 177 INDONESIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 178 INDONESIA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 179 INDONESIA RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 180 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 181 INDONESIA HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 NDONESIA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 183 INDONESIA VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 184 INDONESIA POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 185 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 186 INDONESIA POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 187 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 188 INDONESIA POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 189 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 190 PHILIPPINES GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027, (USD MILLION)
TABLE 191 PHILIPPINES CARDIO METABOLIC TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 192 PHILIPPINES INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 193 PHILIPPINES PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 194 PHILIPPINES CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 195 PHILIPPINES HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 196 PHILIPPINES RAPID COAGULATION TESTING PRODUCTS IN POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
TABLE 197 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY APPLICATION 2018-2027 (USD MILLION)
TABLE 198 PHILIPPINES HAEMATOLOGY IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 199 PHILIPPINES WHOLE BLOOD ANALYSIS IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE , 2018-2027 (USD MILLION)
TABLE 200 PHILIPPINES VITAL SIGN MONITORING IN POINT-OF-CARE TESTING (POCT) MARKET, BY TYPE 2018-2027 (USD MILLION)
TABLE 201 PHILIPPINES POINT OF CARE TESTING MARKET, BY PLATFORM 2018-2027 (USD MILLION)
TABLE 202 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 2018-2027 (USD MILLION)
TABLE 203 PHILIPPINES POINT OF CARE TESTING POINT-OF-CARE TESTING (POCT) MARKET, BY TESTING TYPE 2018-2027 (USD MILLION)
TABLE 204 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 2018-2027 (USD MILLION)
TABLE 205 PHILIPPINES POINT-OF-CARE TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)
TABLE 206 REST OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT , 2018-2027 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET : REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CHRONIC DISEASES AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE ASIA-PACIFIC POINT-OF-CARE (POCT) TESTING MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC POINT-OFCARE (POCT) TESTING MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET
FIGURE 14 EPIDEMIOLOGY OF CHRONIC CONDITIONS (1990-2015)
FIGURE 15 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, 2019
FIGURE 16 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)
FIGURE 17 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
FIGURE 18 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019
FIGURE 20 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 21 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 22 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019
FIGURE 24 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 25 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 26 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , 2019
FIGURE 28 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , 2019-2027 (USD MILLION)
FIGURE 29 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , CAGR (2020-2027)
FIGURE 30 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE , LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, 2019
FIGURE 32 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, 2019-2027 (USD MILLION)
FIGURE 33 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, CAGR (2020-2027)
FIGURE 34 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2019
FIGURE 36 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 37 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2020-2027)
FIGURE 38 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 40 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 41 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 42 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: SNAPSHOT (2019)
FIGURE 44 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2019)
FIGURE 45 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2020 & 2027)
FIGURE 46 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY COUNTRY (2019 & 2027)
FIGURE 47 ASIA-PACIFIC POINT-OF-CARE TESTING (POCT) MARKET: BY TESTING TYPE (2020-2027)
FIGURE 48 ASIA-PACIFIC POINT-OF-CARE (POCT) MARKET: COMPANY SHARE 2019 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
